DITTO seed round brings in $6M for menstrual health supplements

DITTO has raised a $6 million seed round led by FoodLabs, with Eka Ventures returning as an investor, giving the menstrual health startup new capital for its PMS and PMDD supplement business. The DITTO seed round follows a £1.35 million pre-seed led by Eka Ventures in August 2025, bringing disclosed funding to $6 million plus £1.35 million, or about $7.7 million at current exchange rates.

The company did not disclose revenue, valuation or the ownership terms of the round. DITTO was founded in 2024 by Alice van der Schoot, a neuroscientist turned nutrition scientist, and Adam Kugler, a former L’Oréal brand director. Its team has grown to 15 people and includes a gynaecologist and a women’s health GP as medical advisers.

What is DITTO using the seed funding for?

DITTO plans to use the funding to expand its Cycle Supplement, a product aimed at PMS and PMDD symptoms, and to support additional clinical research. Van der Schoot is aiming to run three more clinical trials over the next 12 months and publish five papers, including work examining a possible connection between PMDD and ADHD.

PMDD, or premenstrual dysphoric disorder, is a more severe cycle-related condition than typical PMS and can include significant mood symptoms. DITTO’s stated pitch is that menstrual symptoms are often treated with generic lifestyle advice despite research pointing to broader hormonal, neurological and nutritional factors.

Van der Schoot told Tech Funding News that women in DITTO’s community have been printing the company’s research and taking it to doctors after feeling dismissed in earlier consultations. She contrasted UK healthcare guidance such as abdominal massage or warm baths with data she cited showing that 90% of women experience mild to severe PMS, 86% report cycle-related mood symptoms and 62% report severe pain.

What does DITTO sell?

DITTO’s main product is the Cycle Supplement, co-developed with female scientists including gynaecologist Dr Anita Mitra. The company says the supplement uses beadlet-in-oil delivery technology to time-release 10 clinically supported ingredients.

DITTO says 88% of participants in a clinical trial reported lower symptom severity. That result is central to the investor case, but the company’s research still has to be tested at larger scale.

The company has also built a sizeable audience around menstrual health education. Its community has reached 300,000 members in 18 months, up from 116,000 at the time of its pre-seed round in August 2025. DITTO says the community is helping shape its research priorities, including the planned review of PMDD and ADHD overlap.

Why investors are backing the category

FoodLabs operating partner Flo Breiner said clinical evidence is becoming the entry requirement in menstrual health and that the first company to set that standard will become the reference point for others. Eka Ventures general partner Camilla Dolan said the firm is backing the combination of science and consumer trust.

The PMS and menstrual health supplements category has often leaned on herbal remedies and wellness branding rather than published clinical work. Semaine Health, a New York-based PMS and menopause supplement company, has raised an undisclosed amount from Ocampo Capital. Wile, a plant-based hormonal wellness brand focused on perimenopausal women over 40, raised $3 million in pre-seed funding before being acquired by Nameless CPG in May 2024.

Consumer period-tracking companies such as Flo and Clue operate in adjacent women’s health markets, but they are software businesses rather than supplement manufacturers. Grand View Research valued the global PMS and menstrual health supplements market at $22.6 billion in 2022 and projected it to reach $35 billion by 2030.

This story draws on original reporting from TechFundingNews.